Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
3don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Bristol Surges AbbVie’s setback was viewed as a victory for Bristol Myers Squibb Co., which in late September gained US approval for the first new type of schizophrenia drug in seven decades.
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback